Senses Disorder TRIZ Cases

Stem-loop aptamers bind multiple VEGF-A isoforms with high specificity and potency, helping inhibit angiogenesis and KDR phosphorylation.

Selective CXCR1/CXCR2 inhibition reduces ocular GVHD inflammation and leukocyte infiltration while avoiding the long-term risks of broad corticosteroids.

Salt-modified netarsudil combinations use pH 4.5-5.4 buffering to prevent precipitation, cut dosing frequency, and lower intra-ocular pressure.

A composite PEG 15-hydroxystearate and phospholipid film keeps cyclosporine eye emulsions stable in pH, particle size, and drug encapsulation.

Naphthalene-ring small molecules offer broader treatment for refractory diseases while reducing side effects seen with hormones and immunosuppressants.

Beauvericin at defined micromolar doses inhibits pathological angiogenesis, reduces retinal leakage, and supports retinal structure.

Selective azabicyclo muscarinic modulators target excessive eye growth in myopia while avoiding the side effects of non-selective atropine.

Combining an NSAID with a fatty acid oxidation inhibitor addresses inflammation and metabolic dysregulation to improve glycemic control.

Targeted anti-C1q antibodies block classical complement activation and C1q-driven synapse loss with high specificity for neurodegenerative disease use.

Pre-characterized HLA-restricted T cell banks enable faster selection of allogeneic lines that recognize shared immunodominant epitopes.

AAV delivery of AKT genes helps preserve photoreceptors and visual function when conventional retinal degeneration treatments lose efficacy.

A lipid carrier selectively delivers an anti-inflammatory compound to modulate cytokines and improve chronic inflammation treatment.

Silicon small particles react with water to sustain hydrogen delivery where hydrogen water fades quickly, enabling oxidative stress disease treatment.

A body-temperature-melting hydrogel stabilizes neural retina and RPE cell sheets during handling, then degrades after transplantation for tissue interaction.

Specific heavy and light chain anti-TSLP variants block TSLP signaling to reduce allergic inflammation in asthma and related diseases.

Two rAAV vectors split the otoferlin gene to restore inner ear hair cell function and improve auditory brainstem response.

A yellow transparent ophthalmic viscoelastic improves intraoperative visibility, supports complete removal, and helps shield ocular tissues from UV-blue light.

Excipient and pH tuning helps liquid anti-IL-4R antibody formulations resist aggregation and retain suitable viscosity during storage.

A dilute peptide eye drop uses low buffer and EDTA levels to stay room-temperature stable while easing moderate to severe dry eye symptoms.

A tricyclic formula (I) compound uses substituent and stereochemical tuning to deliver potent EP3 agonist activity for renal disease treatment.

A phosphorylcholine polymer film lets eye drops maintain PHMB preservative efficacy while reducing irritation on dry or damaged corneas.

A buffer-sugar-surfactant formulation stabilizes aflibercept against agitation, freeze-thaw, UV exposure, and high-temperature storage.

Conserved NEFH promoter regions enable compact AAV constructs that drive retinal ganglion cell expression while limiting off-target activity.

Low-temperature high-shear mixing in petrolatum keeps selenium disulfide uniformly dispersed and stable for meibomian gland dysfunction treatment.

Selective Formula I inhibitors improve plasma kallikrein targeting to reduce vascular permeability and inflammation across multiple disorders.

Long-acting compstatin analogs extend complement inhibition through carrier conjugation or PEGylation, helping limit tissue damage.

A pH 4-5 buffered benzyl atropine eye-drop formulation improves aqueous stability and myopia control while minimizing dilation and light sensitivity.

Novel formula (I) EP4 antagonists improve receptor blocking potency to inhibit tumor growth and support treatment of inflammatory disease.

Red-shifted optogenetic AAV therapy paired with neurally coded light restores vision while improving light sensitivity and reducing phototoxicity.

Engineered CFH-FHL polypeptides use linker-separated domains to inhibit complement and reduce lipid buildup in age-related macular degeneration.

Molecular hydrogen and oxyhydrogen ocular formulations reduce inflammation and scarring while improving delivery and lowering treatment toxicity.

Transient OCT4, SOX2, and KLF4 expression via inducible AAV vectors reverses aging marks while preserving cell identity and avoiding teratomas.

Targeted P-domain and bulge mutations improve nucleic acid hybridization specificity, reducing off-target binding during genome editing.

An SNAC-based GLP-1/GIP formulation improves dissolution, stability, and absorption to maintain efficacy with fewer gastrointestinal reactions.

Pre-formed C24-C40 VLCFAs bypass poor metabolic conversion of C20-C22 omega-3s and restore fatty acid levels in target tissues.

Selective ETC targeting is improved by crystalline salts of Compound I that tune physicochemical properties to restore ATP production and limit oxidative damage.

Localized retinal release of an angiogenesis inhibitor improves wet macular degeneration treatment while avoiding rapid vitreous dissipation.

Defined adhesive and low-adhesive culture regions help form a uniform neural retinal progenitor layer and reduce unwanted cell contamination.

PEG sedimentation and size exclusion chromatography isolate young plasma factors that reduce aging markers while avoiding immune response.

A permeable pallet with an integrated resistive heater and rigid airflow path stabilizes vapor dosing across varying inhalation strengths.

Bidirectional CRISPR-AAV constructs target the endogenous RS1 locus to restore retinoschisin expression and address failed XLRS gene therapy endpoints.

Small-molecule C1s inhibitors modulate complement overactivation to preserve synapses and help slow neurodegenerative decline.

A dual-paratope Fab antibody binds VEGF-A and ANG2 independently with high affinity and stability, extending ocular treatment duration and reducing injections.

Stable hydrobromide, sulfate, and succinate crystal forms improve triazine API stability, reduce hygroscopicity, and support safer production.

Engineered VEGFR2 immunoglobulin-like domains with targeted mutations improve stability and dual binding to VEGF-A and VEGF-C for cancer and AMD therapy.

A 7-amino-acid peptide composition suppresses retinal neovascularity, pericyte loss, and vascular leakage with fewer drawbacks than anti-VEGF injections.

Covalently linked cannabinoid and active-agent conjugates target cell surface molecules to combine therapeutic effects with better delivery specificity.

Small molecules block uPAR-FPRs signaling to reduce cell adhesion and migration, targeting systemic sclerosis at its molecular basis.

A chimeric VR3.0 channelrhodopsin combines fast photoresponse with high light sensitivity to restore retinal photosensitivity under broad-wavelength light.

Excluding reactive excipients keeps linagliptin-SGLT2 solid dosage forms stable while preserving content uniformity and bioavailability.

Amide compounds inhibit RORγ activity to reduce IL-17 production and Th17 cell differentiation, addressing limited efficacy in autoimmune disease treatments.

Caprylic and capric acid degrade neutral lipids in cardiac blood vessels, restoring vascular function where cholesterol-lowering drugs fail.

Modified isoquinoline structures lower intraocular pressure while reducing toxicity and side effects.

Peptides featuring a linker biradical modulate VEGF expression levels to influence angiogenesis.

Pyridine-2-amide compounds selectively bind to CB2 receptors, reducing unwanted CB1 activity to treat pain and inflammation.

Alanylglutamine dipeptide improves stability while maintaining glutamine supply to counteract vision decline during physical exertion.

Reduces toxicity by replacing persistent agents with degradable carbodiimides while maintaining adhesive strength for surgical closure.

Intratympanic injection of biodegradable microspheres forms a sustained-release film on the round window membrane, reducing treatment frequency.

Aryl cyclopropyl-amino-isoquinolinyl amide compounds modulate kinase activity to treat ocular disorders.

Novel aliphatic prolinamide derivatives inhibit HTRA1 protease activity, addressing insufficient disease progression control in current AMD treatments.

Lopap protease prevents apoptosis and increases cell viability, addressing tissue degeneration by stimulating extracellular matrix protein expression.

Masking the C-17 carbonyl as a ketimine improves aqueous solubility and bioavailability of 17β-HSD1 inhibitors while preserving selective enzyme inhibition.

Modified nucleic acid structures inhibit receptor interactions, reducing lesions while avoiding drug toxicity.

Nitrogen evaporation removes ethanol from cyclosporin A oil solutions to create stable ophthalmic emulsions.

Combining RPL554 with muscarinic antagonists potentiates bronchodilation through synergistic pharmacological activity.

P2Y6 receptor agonists activate neuronal signaling pathways to treat neurodegenerative disorders and traumatic CNS injury.

A chimeric neurotoxin links LH N and H C domains via a preserved 3_10 helix to maintain structural integrity.

Novel Formula I compounds inhibit sodium-dependent glucose cotransporters to enhance urinary glucose excretion.

N-acetylcysteine amide prodrugs penetrate retinal tissues to elevate intracellular glutathione levels.

Segmented triazepine scaffolds optimize BRD4 binding affinity to resolve inadequate disease management.

A monoclonal MASP-2 antibody selectively blocks the lectin complement pathway.

Tetrahydroquinoline compounds inhibit phospholipase C activity to resolve excessive TSH receptor activation in hyperthyroidism.

Formula II compounds target Tau aggregates to resolve off-target binding issues in Alzheimer's diagnosis.

A nitric oxide releasing phosphodiesterase type 5 inhibitor uses an enzymatic cleavable bond to sustain intraocular pressure reduction.